What's Happening?
Revvity, Inc. has announced a program to expand its type 1 diabetes (T1D) detection capabilities, supported by Sanofi. The initiative includes developing a population-scale assay for early detection of T1D, based on Revvity's existing research-use assay. The collaboration aims to accelerate the transition to a new clinical standard of care, enabling early diagnosis and intervention to prevent disease progression. Regulatory submissions are planned for the U.S. FDA and other jurisdictions.
Why It's Important?
Early detection of T1D can significantly improve patient outcomes by allowing timely interventions to prevent complications. This program represents a pivotal step in advancing the standard of care for T1D, potentially reducing the burden of the disease on patients and healthcare systems. The collaboration with Sanofi highlights the importance of partnerships in driving innovation and expanding access to diagnostic tools.
What's Next?
Revvity plans to validate the new assay in additional locations across its global laboratory network, facilitating worldwide access for clinical use. The company will continue to collaborate with Sanofi to expand access to its existing products and support regulatory submissions. Successful implementation of this program could lead to widespread adoption of early-stage T1D screening in clinical practice.
